Role of molecular pathology in the treatment of anaplastic gliomas and glioblastomas

Research output: Contribution to journalArticlepeer-review

Abstract

The 2016 WHO Classification of Tumors of the Central Nervous System integrated molecular biomarkers into the classifications of malignant gliomas. Several markers now play a key role in our understanding of these tumors and are integral for clinical decision-making; these include codeletion of 1p and 19q and IDH1 and IDH2 mutations. The presentation by Matthias Holdhoff, MD, PhD, at the NCCN 23rd Annual Conference discussed the current understanding of anaplastic gliomas (WHO grade III) in the context of the new classification and its implications on clinical practice. The 2018 NCCN Guidelines for Central Nervous System Cancers incorporate molecular and histologic characteristics in the staging and treatment of both low- and high-grade gliomas (WHO grades II-IV).

Original languageEnglish (US)
Pages (from-to)642-645
Number of pages4
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume16
Issue number5S
DOIs
StatePublished - May 1 2018

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Role of molecular pathology in the treatment of anaplastic gliomas and glioblastomas'. Together they form a unique fingerprint.

Cite this